Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy

July 13, 2010

New Rochelle, NY, July 13, 2010--Improved delivery methods and better testing systems are needed to advance promising gene therapy strategies for treating prostate cancer, according to a series of review articles in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc (www.liebertpub.com). The articles and an accompanying editorial are available free online at www.liebertpub.com/hum

Prostate cancer is one of the most common types of cancer affecting men in the U.S. and is the second leading cause of cancer death among men, after lung cancer. Among the most recent treatment strategies being tested against prostate cancer is gene therapy, in which a gene product intended to destroy the tumor cells or to stimulate the patient's immune system to fight the cancer is delivered to the tumor, typically using a viral delivery vector. The most common approach uses an adenovirus as the delivery vector and has been shown to be quite safe.

However, it is still not clear which genes, viral vectors, or strategies are optimal to ensure targeted delivery of the genes to the tumor cells, and uptake by the tumor, to achieve the most effective, most potent, and safest treatment that can lead to a cure for prostate cancer. Stefan Kochanek, from the University of Ulm, Germany, and Bernd Gänsbacher, from the Technical University of Munich, Germany, present their views on the need for developing and testing new and innovative approaches in the editorial entitled, "Prostate Cancer Gene Therapy: Attempts to Innovate."

Three review articles in the issue explore various aspects of this evolving field and advances that will make it possible to translate new gene therapy techniques from research to testing in human patients. Ellen Schenk and colleagues from Erasmus Medical Center, The Netherlands, and Uppsala University, Sweden, representing the GIANT FP6 Consortium, review current clinical experiences and progress toward the development of adenovirus-mediated gene therapy in the review article entitled, "Clinical Adenoviral Gene Therapy for Prostate Cancer."

Norman Maitland and coauthors from University of York, U.K., Uppsala University, Sweden, and Erasmus Medical Center, The Netherlands, on behalf of the GIANT FP6 Consortium, emphasize the need for laboratory models that more closely mirror human tissues in the article entitled, "Gene Transfer Vectors Targeted to Human Prostate Cancer: Do We Need Better Preclinical Testing Systems?"

Jeroen de Vrij and colleagues from Leiden University Medical Center and Erasmus Medical Center, The Netherlands, and from Got-a-Gene, in Kullavik, Sweden, also representing the GIANT FP6 Consortium, summarize recent advances in adenovirus technology and present state-of-the-art and future prospects for adenoviral vector-based gene therapy in the article entitled, "Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy."

"Achievement of the full potential of gene transfer technologies will depend upon understanding the basic concepts of carcinogenesis in the prostate," says Bernd Gänsbacher, MD, PhD, Deputy Editor of Human Gene Therapy and Director, Institute for Experimental Oncology, Technical University of Munich, Germany.
-end-
Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies is the authoritative peer-reviewed journal published monthly in print and online that presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Tables of content and a free sample issue may be viewed online at www.liebertpub.com/hum

Mary Ann Liebert, Inc. (www.liebertpub.com), is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering Parts A, B, and C; Stem Cells and Development; and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available at www.liebertpub.com.

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101

Mary Ann Liebert, Inc./Genetic Engineering News

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.